<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-09T03:10:12Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/12242" metadataPrefix="oai_dc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/12242</identifier><datestamp>2026-10-08T00:05:53Z</datestamp><setSpec>com_10259_6168</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_12236</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>SWI/SNF alterations in cancer: molecular targets and therapeutic implications</dc:title>
<dc:creator>Monteverde, Beatriz</dc:creator>
<dc:creator>Moreno, Thaidy</dc:creator>
<dc:creator>Fuente Vivas, Dalia de la</dc:creator>
<dc:creator>Revilla, Carlos</dc:creator>
<dc:creator>Casar, Berta</dc:creator>
<dc:creator>Crespo, Piero</dc:creator>
<dc:creator>Varela, Ignacio</dc:creator>
<dc:subject>Cromatina</dc:subject>
<dc:subject>Genética médica</dc:subject>
<dc:subject>Chromatin</dc:subject>
<dc:subject>Medical genetics</dc:subject>
<dc:description>Póster presentado en: 42 Congress SEBBM, Madrid, 16-19 july 2019</dc:description>
<dc:description>Background:&#xd;
SWI/SNF chromatin remodelling complex is altered in nearly 20% of all human tumor types, which places it as the most broadly&#xd;
mutated molecular system in human cancer, just after TP53 [1, 2]. Nevertheless, the molecular mechanisms through which these&#xd;
alterations foster cancer development remain to be fully understood. In addition, any potential susceptibility associated with&#xd;
SWI/SNF alterations might be exploited for the treatment of patients affected by different malignancies.&#xd;
Methodology:&#xd;
We have generated stably-transduced cell lines for a doxycycline-inducible vector that directs the expression of different shRNAs&#xd;
targeting ARID1A, ARID1B or ARID2 in different human cancer cell lines. We have studied the transcriptional alterations resulted&#xd;
from the deficiency of these subunits in different cellular contexts by RNA-Seq, as well as the changes in chromatin accessibility&#xd;
by ATAC-Seq. Additionally, we have studied the sensitivity of these cell lines to different antitumoral treatments.&#xd;
Results:&#xd;
We have identified molecular pathways differently expressed in the SWI/SNF-deficient cell lines that might explain some&#xd;
characteristics of the behaviour of these tumor cells. Thus, we have seen an overexpression of genes involved in ROS production,&#xd;
as well as genes encoding metallopeptidases, and a downregulation of genes related to cellular adhesion or tumor suppression.&#xd;
Finally, we have detected different sensitivities in the ARID-deficient cells to some treatments, like cis-platin, and PARP or EGFR&#xd;
inhibitors.</dc:description>
<dc:date>2026-10-07T10:37:01Z</dc:date>
<dc:date>2026-10-07T10:37:01Z</dc:date>
<dc:date>2019</dc:date>
<dc:type>info:eu-repo/semantics/conferenceObject</dc:type>
<dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
<dc:identifier>https://hdl.handle.net/10259/12242</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:format>application/pdf</dc:format>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>